Tuesday, May 16, 2023 2:37:05 PM
Strong buy ther
Ther stock good news..will go back to .10 soon
Theralink Technologies is a precision medicine company with a nationally CLIA-certified and CAP-accredited laboratory in Golden, Colorado. Theralink’s unique and patented Reverse Phase Protein Array (RPPA) technology platform can quantify protein signaling to support oncology clinical treatment decisions and biopharmaceutical drug development. Since protein signaling is responsible for the development and progression of cancer, nearly all FDA-approved cancer therapeutics target proteins, not genes. The Theralink® RPPA technology can reveal the protein drug target(s) that are essentially turned “on” in a patient’s cancer and suggest the most effective treatment plan to turn those proteins “off”. Therefore, the Theralink® RPPA technology is a critical tool that empowers oncologists with actionable information to effectively treat a cancer patient, which is often missed by standard proteomic and genomic testing.
Our commercially available Lab Developed Test (LDT), the Theralink® Assay for Breast Cancer, is currently being utilized by oncologists across the United States to assist in making the most targeted treatment plan for their patients with advanced breast cancer. In 2023, Theralink began receiving reimbursement for this test by Medicare and certain third-party payors. The Theralink® test determines which drug target(s) are present and/or activated to reveal to the oncologist which patients are predicted to be responders versus non-responders to a particular therapeutic. The test provides therapeutic recommendations to support oncologist treatment selection of the best therapy option – which may improve patient response and consequently save the healthcare system
Treatment options for other cancers too
Recent PALI News
- Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules • GlobeNewswire Inc. • 05/02/2024 12:30:00 PM
- Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS) • GlobeNewswire Inc. • 05/01/2024 12:30:00 PM
- Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach • GlobeNewswire Inc. • 04/23/2024 12:30:00 PM
- Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool • GlobeNewswire Inc. • 04/16/2024 12:30:00 PM
- Palisade Bio to Participate in the Virtual Investor Lunch Break Event • GlobeNewswire Inc. • 04/11/2024 01:15:00 PM
- Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™ • GlobeNewswire Inc. • 04/10/2024 12:15:00 PM
- Palisade Bio Announces 1-for-15 Reverse Stock Split • GlobeNewswire Inc. • 04/03/2024 09:30:00 PM
- Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/27/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:35:16 PM
- Palisade Bio to Present at Digestive Disease Week (DDW) 2024 • GlobeNewswire Inc. • 02/15/2024 01:35:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:54:03 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:10:04 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:38:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 08:08:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 08:08:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 08:08:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 08:08:36 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/13/2024 07:51:09 PM
- Palisade Bio Provides Corporate Update and Reiterates Guidance • GlobeNewswire Inc. • 02/13/2024 01:35:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/09/2024 09:03:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/08/2024 09:38:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/08/2024 09:37:40 PM
- Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members • GlobeNewswire Inc. • 02/08/2024 07:40:00 PM
- Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders • GlobeNewswire Inc. • 02/08/2024 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 01:30:10 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM